Pacific Biosciences of California - PACB Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PACB shares.
View PACB analyst ratings or view top-rated stocks.

4 analysts have issued twelve-month target prices for Pacific Biosciences of California's stock. Their PACB share price forecasts range from $6.00 to $40.00. On average, they expect the company's share price to reach $17.40 in the next twelve months. This suggests a possible upside of 199.7% from the stock's current price.
View analysts price targets for PACB or view top-rated stocks among Wall Street analysts.

Pacific Biosciences of California's stock was trading at $20.46 at the beginning of 2022. Since then, PACB stock has decreased by 71.6% and is now trading at $5.8050.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our PACB earnings forecast.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) announced its quarterly earnings results on Wednesday, August, 3rd. The biotechnology company reported ($0.34) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.34). The biotechnology company had revenue of $35.47 million for the quarter, compared to the consensus estimate of $35.54 million. Pacific Biosciences of California had a negative net margin of 147.39% and a negative trailing twelve-month return on equity of 35.76%. During the same quarter in the previous year, the firm earned ($0.21) earnings per share.

Pacific Biosciences of California updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $138.00 million-$145.00 million, compared to the consensus revenue estimate of $161.95 million.

2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PACB stock can currently be purchased for approximately $5.81.

Pacific Biosciences of California (NASDAQ:PACB) has a market capitalization of $1.31 billion and generates $130.51 million in revenue each year. The biotechnology company earns $-181,220,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

The company employs 728 workers across the globe.

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The official website for the company is www.pacb.com. The biotechnology company can be reached via phone at (650) 521-8000, via email at ir@pacb.com, or via fax at 302-636-5454.